ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy
Addition of asciminib to imatinib led to higher rate of DMR vs continued imatinib or switch to nilotinib in patients with chronic-phase chronic myeloid leukemia not achieving DMR with ≥1 year of imatinib therapy.